Publications by authors named "Brandon Elpers"

Claim this Profile
E
Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.
Michael Kreuter, Toby M Maher, Wim A Wuyts, Claudia Valenzuela, Mark Hamblin, Brandon Elpers

Chest· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis.
Negar Golchin, Aditya Patel, Julia Scheuring, Victoria Wan, Kimberly Hofer, Brandon Elpers

BMC Pulm Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Admilparant, an LPA Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Tamera J Corte, Juergen Behr, Vincent Cottin, Marilyn K Glassberg, Michael Kreuter, Brandon Elpers

Am J Respir Crit Care Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States.
Ying Qiu, Julia Zhu, Pooja Chopra, Brandon Elpers, Christopher Dieyi

Ther Adv Respir Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).
Tamera J Corte, Lisa Lancaster, Jeffrey J Swigris, Toby M Maher, Jonathan G Goldin, Brandon Elpers

BMJ Open Respir Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis